Glycemic index and satiety
1Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St., Boston, MA 02111, USA.
Summary
Consuming low-glycemic index (GI) carbohydrates may help obese individuals lose weight by reducing hunger and subsequent energy intake. Further long-term research is needed, but current evidence supports low-GI diets for weight management.
Area of Science:
- Nutrition Science
- Metabolic Health
- Obesity Research
Background:
- Obesity is a major public health concern.
- Weight management strategies often focus on caloric restriction.
- Dietary glycemic index (GI) influences postprandial glycemic response and satiety.
Purpose of the Study:
- To investigate the effect of low-glycemic index (GI) carbohydrate consumption on energy intake in obese individuals seeking weight loss.
- To assess the potential of low-GI carbohydrates in weight management regimens.
Main Methods:
- Short-term investigations were reviewed.
- Comparison of energy intake following consumption of low-GI versus higher-GI carbohydrates.
Main Results:
- Short-term studies suggest low-GI carbohydrates may delay hunger.
- Consumption of low-GI carbohydrates may reduce subsequent energy intake compared to higher-GI options.
Conclusions:
- Low-glycemic index (GI) carbohydrates show potential for aiding weight loss in obese individuals.
- Further long-term studies are required to confirm the role of GI in weight regulation.
- Low-GI carbohydrates may be a useful component of weight-reducing diets.
Related Concept Videos
01:30Regulation of Food Intake
2.3K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.3K
01:02Glucose Homeostasis: Regulation of Blood Glucose
3.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K
01:23Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
01:24Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
01:06Oral Hypoglycemic Agents: Glinides
573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
01:16Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K